Immunotherapy in advanced non-small-cell lung cancer withEGFRmutations

被引：2

作者：

Liu, Fangfang ^{[1
]}

Yuan, Xun ^{[1
]}

Jiang, Jizong ^{[1
]}

Chu, Qian ^{[1
]}

机构：

[1] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Tongji Med Coll, Wuhan 430030, Peoples R China

来源：

IMMUNOTHERAPY | 2020年 / 12卷 / 16期

基金：

中国国家自然科学基金;

关键词：

EGFRmutation; immune checkpoint inhibitors; immunotherapy; NSCLC; PD-L1; LIGAND; 1; EXPRESSION; PD-L1; OPEN-LABEL; 1ST-LINE TREATMENT; EGFR MUTATIONS; ADVANCED NSCLC; T790M STATUS; PHASE-III; NIVOLUMAB; ADENOCARCINOMA;

D O I：

10.2217/imt-2020-0148

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

EGFR-tyrosine kinase inhibitors (EGFR-TKIs) had been regarded as the front-line treatment for advanced non-small-cell lung cancer (NSCLC) patients withEGFRmutations. However, resistance to EGFR-TKIs is inevitable, it remains a major challenge. Immune checkpoint inhibitors (ICIs) had shown superior clinical efficacy in many types of solid tumors, while it exhibited impaired overall efficacy in NSCLC with EGFRmutations. In this review, we will perform a meta-analysis to assess the relationship between the programmed death ligand 1 (PD-L1) expression and clinical benefit of EGFR-TKIs. We also overview the immunotherapy in advanced NSCLC patients withEGFRmutations to investigate the potential biomarkers predicting the ICIs efficiency, and the subgroups that could benefit from ICIs treatment.

引用

页码：1195 / 1207

页数：13

共 78 条

[1] Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression [J].

Aguilar, E. J. ;

Ricciuti, B. ;

Gainor, J. F. ;

Kehl, K. L. ;

Kravets, S. ;

Dahlberg, S. ;

Nishino, M. ;

Sholl, L. M. ;

Adeni, A. ;

Subegdjo, S. ;

Khosrowjerdi, S. ;

Peterson, R. M. ;

Digumarthy, S. ;

Liu, C. ;

Sauter, J. ;

Rizvi, H. ;

Arbour, K. C. ;

Carter, B. W. ;

Heymach, J. V. ;

Altan, M. ;

Hellmann, M. D. ;

Awad, M. M. .

ANNALS OF ONCOLOGY, 2019, 30 (10) :1653-1659

[2] Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial [J].

Ahn, M. -J. ;

Yang, J. ;

Yu, H. ;

Saka, H. ;

Ramalingam, S. ;

Goto, K. ;

Kim, S. -W. ;

Yang, L. ;

Walding, A. ;

Oxnard, G. R. .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) :S115-S115

[3] Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors [J].

Akbay, Esra A. ;

Koyama, Shohei ;

Carretero, Julian ;

Altabef, Abigail ;

Tchaicha, Jeremy H. ;

Christensen, Camilla L. ;

Mikse, Oliver R. ;

Cherniack, Andrew D. ;

Beauchamp, Ellen M. ;

Pugh, Trevor J. ;

Wilkerson, Matthew D. ;

Fecci, Peter E. ;

Butaney, Mohit ;

Reibel, Jacob B. ;

Soucheray, Margaret ;

Cohoon, Travis J. ;

Janne, Pasi A. ;

Meyerson, Matthew ;

Hayes, D. Neil ;

Shapiro, Geoffrey I. ;

Shimamura, Takeshi ;

Sholl, Lynette M. ;

Rodig, Scott J. ;

Freeman, Gordon J. ;

Hammerman, Peter S. ;

Dranoff, Glenn ;

Wong, Kwok-Kin .

CANCER DISCOVERY, 2013, 3 (12) :1355-1363

[4] Anti-CD73 in Cancer Immunotherapy: Awakening New Opportunities [J].

Antonioli, Luca ;

Yegutkin, Gennady G. ;

Pacher, Pal ;

Blandizzi, Corrado ;

Hasko, Gyorgy .

TRENDS IN CANCER, 2016, 2 (02) :95-109

[5] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[6] Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population [J].

Brzezianska, Ewa ;

Karbownik, Malgorzata ;

Migdalska-Sek, Monika ;

Pastuszak-Lewandoska, Dorota ;

Wloch, Jan ;

Lewinski, Andrzej .

MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2006, 599 (1-2) :26-35

[7] First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer [J].

Carbone, D. P. ;

Reck, M. ;

Paz-Ares, L. ;

Creelan, B. ;

Horn, L. ;

Steins, M. ;

Felip, E. ;

van den Heuvel, M. M. ;

Ciuleanu, T. -E. ;

Badin, F. ;

Ready, N. ;

Hiltermann, T. J. N. ;

Nair, S. ;

Juergens, R. ;

Peters, S. ;

Minenza, E. ;

Wrangle, J. M. ;

Rodriguez-Abreu, D. ;

Borghaei, H. ;

Blumenschein, G. R. ;

Villaruz, L. C. ;

Havel, L. ;

Krejci, J. ;

Corral Jaime, J. ;

Chang, H. ;

Geese, W. J. ;

Bhagavatheeswaran, P. ;

Chen, A. C. ;

Socinski, M. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) :2415-2426

[8] Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples [J].

Casadevall, David ;

Clave, Sergi ;

Taus, Alvaro ;

Hardy-Werbin, Max ;

Rocha, Pedro ;

Lorenzo, Marta ;

Menendez, Silvia ;

Salido, Marta ;

Albanell, Joan ;

Pijuan, Lara ;

Arriola, Edurne .

CLINICAL LUNG CANCER, 2017, 18 (06) :682-+

[9] PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy [J].

Chen, Kaiyan ;

Cheng, Guoping ;

Zhang, Fanrong ;

Zhu, Guanxia ;

Xu, Yanjun ;

Yu, Xiaoqing ;

Huang, Zhiyu ;

Fan, Yun .

LUNG CANCER, 2020, 142 :98-105

[10] CD73: an emerging checkpoint for cancer immunotherapy [J].

Chen, Siqi ;

Wainwright, Derek A. ;

Wu, Jennifer D. ;

Wan, Yong ;

Matei, Daniela E. ;

Zhang, Yi ;

Zhang, Bin .

IMMUNOTHERAPY, 2019, 11 (11) :983-997

← 1 2 3 4 5 6 7 8 →